What are Tetracycline antibiotic + retinoid combination drugs?

Tetracycline antibiotic + retinoid combination drugs are pharmacologic agents that share a common mechanism (typically targeting Bacterial ribosome (minocycline); retinoic acid receptors (tretinoin)). 6 are currently marketed, with 1 more in clinical development.

What are the marketed Tetracycline antibiotic + retinoid combination drugs?

Marketed Tetracycline antibiotic + retinoid combination drugs include Minocycline plus tretinoin, Etanercept + Acitretin, efalizumab plus acitretin, Dapsone; Tretinoin, Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%, Duobrii®.

Tetracycline antibiotic + retinoid combination

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

6 marketed 1 in Phase 3

This page covers all Tetracycline antibiotic + retinoid combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Bacterial ribosome (minocycline); retinoic acid receptors (tretinoin), TNF-α receptor (p75/p55) + retinoid X receptor (RXR) and retinoic acid receptor (RAR), CD11a (LFA-1) + retinoid X receptor (RXR) / retinoid acid receptor (RAR).

Targets

Bacterial ribosome (minocycline); retinoic acid receptors (tretinoin) · TNF-α receptor (p75/p55) + retinoid X receptor (RXR) and retinoic acid receptor (RAR) · CD11a (LFA-1) + retinoid X receptor (RXR) / retinoid acid receptor (RAR) · Retinoic acid receptors (RAR-α, RAR-β, RAR-γ) · Glucocorticoid receptor (halobetasol); retinoic acid receptors (tazarotene)

Marketed (6)

Minocycline plus tretinoin · Derm Research @ 888 Inc. · Dermatology
Minocycline is a tetracycline antibiotic with anti-inflammatory properties, while tretinoin is a retinoid that promotes skin cell turnover and reduces sebum production; together they target bacterial infection and inflammation in acne.
Etanercept + Acitretin · Pfizer · Dermatology / Immunology
Etanercept blocks TNF-α signaling while acitretin normalizes keratinocyte differentiation and reduces inflammation, together targeting both immune and skin-barrier dysfunction in psoriasis.
efalizumab plus acitretin · Universita di Verona · Dermatology/Immunology
Efalizumab blocks T-cell activation and migration to skin while acitretin reduces keratinocyte proliferation and differentiation, together providing dual immunological and differentiation-based control of psoriasis.
Dapsone; Tretinoin · Allergan · Dermatology
This combination of dapsone (an antimicrobial and anti-inflammatory agent) and tretinoin (a retinoid that promotes skin cell turnover) works synergistically to reduce inflammation and normalize skin cell differentiation in acne and rosacea.
Adapalene Gel, 0.1% + Tazarotene Cream, 0.1% · Galderma R&D · Dermatology
This combination product delivers two retinoid receptor agonists that normalize skin cell differentiation and reduce inflammation to treat acne and photoaging.
Duobrii® · Icahn School of Medicine at Mount Sinai · Dermatology
Duobrii is a fixed-dose combination of halobetasol propionate (a potent topical corticosteroid) and tazarotene (a retinoid) that reduces inflammation and normalizes skin cell differentiation in psoriasis.

Phase 3 pipeline (1)

Duobrii 0.01 % / 0.045 % Topical Lotion · Austin Institute for Clinical Research · Dermatology
Duobrii combines halobetasol propionate (a potent corticosteroid) and tazarotene (a retinoid) to reduce inflammation and normalize skin cell differentiation in psoriasis.

Patent intelligence

retinoid combination patent landscape — aggregated cliff calendar, attackable patents, originator estates